⌘K
t
Tissue Regenix Group plc provided an update on 8 December 2025 regarding the proposed cancellation of its shares. The Company expects to remain solvent if Resolutions pass at a General Meeting on 22 December 2025 and an initial £7.5m of a Secured Convertible Loan Note is drawn down. Trading in Ordinary Shares will remain suspended ahead of the 7 January 2026 Cancellation, after which a matched bargain facility will be available for shareholders for at least a year.
| Date | 8 Dec 2025 |
| Time | 07:00:11 |
| Category | Miscellaneous |
| ID | 6180K |
Tissue Regenix Group plc
('Tissue Regenix', the 'Group' or the 'Company')
Update re. proposed cancellation of shares
Tissue Regenix (AIM: TRX), the regenerative medical devices company, provides a further update on the proposed cancellation of its shares.
Further to the announcement of 4 December 2025, the Company expects to remain solvent assuming that the Resolutions are passed at the General Meeting on 22 December 2025 and the initial £7.5m of the Secured Convertible Loan Note is drawn down shortly thereafter.
However, in light of the ongoing financial challenges facing the Company and continued uncertainty over its current trading position, the Board does not believe it will be able to clarify Tissue Renegix's financial position with any degree of certainty ahead of the proposed Cancellation date. As a result, trading in the Ordinary Shares will remain suspended ahead of Cancellation on 7 January 2026.
There will be a matched bargain facility in place from 7 January 2026 for a period of at least a year which will allow Shareholders to trade on a matched bargain basis.
Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the announcement made by the Company on 4 December 2025.
For more information, please contact:
|
Tissue Regenix Group plc |
|
|
Jay LeCoque, Executive Chairman
|
via Walbrook PR |
|
Cavendish Capital Markets (Nominated Adviser and Broker) |
|
|
Geoff Nash/Giles Balleny/Edward Whiley Nigel Birks - Life Science Specialist Sales Harriet Ward - ECM |
Tel: +44 (0) 20 7466 5000 |
|
Walbrook PR (Financial PR and IR) |
Tel: +44 (0)20 7933 8780 |
|
Alice Woodings / Lianne Applegarth |
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.